JS Link
Financials
Valuation Metrics
JS Link's Market Cap is ₩1.2T. At end of 2025 it was ₩6616B. Ranked #286 of 2,421 in KR market (top 12%), #75 of 1,640 on KOSDAQ (top 5%), #31 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 13%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.17T KRW | KR#286/2,421 Sec#31/231 |
| Revenue | 22.78B KRW | KR#2,110/2,421 Sec#152/231 |
| Net Income | -5.30B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 187.70B KRW | KR#1,356/2,421 Sec#99/231 |
| Net Assets | 103.50B KRW | KR#1,390/2,421 Sec#110/231 |
| Employees | 80 | KR#1,810/2,421 Sec#152/231 |
| Value | ||
| P/B | 11.26x | KR#2,365/2,421 Sec#213/231 |
| P/S | 51.17x | KR#2,374/2,421 Sec#197/231 |
| FCF Yield | -4.58% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -5.12% | KR#1,804/2,421 Sec#130/231 |
| ROA | -2.82% | KR#1,820/2,421 Sec#128/231 |
| Op. Margin | -63.17% | KR#2,257/2,421 Sec#162/231 |
| Revenue Growth | 51.26% | KR#201/2,421 Sec#27/231 |
| Financial Health | ||
| Debt Ratio | 81.35% | KR#1,368/2,421 Sec#159/231 |
| Total Debt | 54.14B KRW | KR#976/2,421 Sec#66/231 |
| FCF | -53.44B KRW | KR#2,090/2,421 Sec#206/231 |
| Cash | 72.23B KRW | KR#592/2,421 Sec#31/231 |
| Current Ratio | 1.55x | KR#1,161/2,421 Sec#127/231 |
| Performance | ||
| 1Y Return | 58.04% | KR#237/2,421 Sec#10/231 |
| 1M Return | -14.31% | KR#2,224/2,421 Sec#188/231 |
| From 52W High | -36.97% | KR#798/2,421 Sec#54/231 |
| 1Y MDD | -43.25% | KR#701/2,421 Sec#53/231 |
| Trading | ||
| Volume | 65,177 shares | KR#996/2,421 Sec#101/231 |
| Trading Value | 2.08B KRW | KR#551/2,421 Sec#53/231 |
| Foreign Own. | 3.41% | KR#1,175/2,421 Sec#107/231 |
| Per Share | ||
| EPS | -143 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,792 KRW | KR#1,903/2,421 Sec#146/231 |
Company Info
Established in 2000 as a personalized medicine specialized healthcare company, the company will change its name to JS Link in 2025. It operates genome analysis technology-based services and molecular diagnostics businesses. Through an amendment to its articles of incorporation, JS Link is expanding into the production of permanent sintered magnets for future industries like electric vehicles and robots. The company is preparing for manufacturing by securing rare earth procurement partnerships, talent, and facility investments, while pursuing innovation in its technology platform. JS Link is headquartered in Gangseo-gu, Seoul Metropolitan City.